Search

Your search keyword '"Egeler, R. Maarten"' showing total 527 results
Start Over Author "Egeler, R. Maarten"
527 results on '"Egeler, R. Maarten"'

1. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study

Author

Kemps, Paul G., Zondag, Timo C. E., Arnardóttir, Helga B., Solleveld-Westerink, Nienke, Borst, Jelske, Steenwijk, Eline C., van Egmond, Demi, Swennenhuis, Joost F., Stelloo, Ellen, Trambusti, Irene, Verdijk, Robert M., van Noesel, Carel J. M., Cleven, Arjen H. G., Scheijde-Vermeulen, Marijn A., Koudijs, Marco J., Krsková, Lenka, Hawkins, Cynthia, Egeler, R. Maarten, Brok, Jesper, von Bahr Greenwood, Tatiana, Svojgr, Karel, Beishuizen, Auke, van Laar, Jan A. M., Pötschger, Ulrike, Hutter, Caroline, Sieni, Elena, Minkov, Milen, Abla, Oussama, van Wezel, Tom, van den Bos, Cor, and van Halteren, Astrid G. S.

Published
2023
Full Text
View/download PDF

2. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

Author

Burke, Michael J, Verneris, Michael R, Le Rademacher, Jennifer, He, Wensheng, Abdel-Azim, Hisham, Abraham, Allistair A, Auletta, Jeffery J, Ayas, Mouhab, Brown, Valerie I, Cairo, Mitchell S, Chan, Ka Wah, Diaz Perez, Miguel A, Dvorak, Christopher C, Egeler, R Maarten, Eldjerou, Lamis, Frangoul, Haydar, Guilcher, Gregory MT, Hayashi, Robert J, Ibrahim, Ahmed, Kasow, Kimberly A, Leung, Wing H, Olsson, Richard F, Pulsipher, Michael A, Shah, Niketa, Shah, Nirali N, Thiel, Elizabeth, Talano, Julie-An, and Kitko, Carrie L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Stem Cell Research, Pediatric, Pediatric Cancer, Transplantation, Hematology, Clinical Research, Rare Diseases, Stem Cell Research - Nonembryonic - Human, Cancer, Childhood Leukemia, Regenerative Medicine, Genetics, Academic Medical Centers, Acute Disease, Adolescent, Bone Marrow Transplantation, Child, Child, Preschool, Chronic Disease, Female, Graft vs Host Disease, Humans, Immunosuppressive Agents, International Cooperation, Male, Myeloablative Agonists, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Prospective Studies, Recurrence, Remission Induction, Severity of Illness Index, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, T-cell ALL, Relapse, Acute lymphoblastic leukemia, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well described. Two hundred twenty-nine children with T-ALL in second complete remission (CR2) received an HCT after myeloablative conditioning between 2000 and 2011 and were reported to the Center for International Blood and Marrow Transplant Research. Median age was 10 years (range, 2 to 18). Donor source was umbilical cord blood (26%), matched sibling bone marrow (38%), or unrelated bone marrow/peripheral blood (36%). Acute (grades II to IV) and chronic graft-versus-host disease occurred in, respectively, 35% (95% confidence interval [CI], 27% to 45%) and 26% (95% CI, 20% to 33%) of patients. Transplant-related mortality at day 100 and 3-year relapse rates were 13% (95% CI, 9% to 18%) and 30% (95% CI, 24% to 37%), respectively. Three-year overall survival and disease-free survival rates were 48% (95% CI, 41% to 55%) and 46% (95% CI, 39% to 52%), respectively. In multivariate analysis, patients with bone marrow relapse, with or without concurrent extramedullary relapse before HCT, were most likely to relapse (hazard ratio, 3.94; P = .005) as compared with isolated extramedullary disease. In conclusion, HCT for pediatric T-ALL in CR2 demonstrates reasonable and durable outcomes, and consideration for HCT is warranted.

Published
2015

4. Challenges and Opportunities for International Cooperative Studies in Pediatric Hematopoeitic Cell Transplantation: Priorities of the Westhafen Intercontinental Group

Author

Schultz, Kirk R, Baker, Kevin Scott, Boelens, Jaap J, Bollard, Catherine M, Egeler, R Maarten, Cowan, Mort, Ladenstein, Ruth, Lankester, Arjan, Locatelli, Franco, Lawitschka, Anita, Levine, John E, Loh, Mignon, Nemecek, Eneida, Niemeyer, Charlotte, Prasad, Vinod K, Rocha, Vanderson, Shenoy, Shalini, Strahm, Brigitte, Veys, Paul, Wall, Donna, Bader, Peter, Grupp, Stephan A, Pulsipher, Michael A, and Peters, Christina

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Pediatric, Clinical Trials and Supportive Activities, Pediatric Research Initiative, Stem Cell Research, Clinical Research, Hematology, Transplantation, Regenerative Medicine, Adolescent, Age Factors, Child, Hematopoietic Stem Cell Transplantation, Humans, International Cooperation, Transplantation, Homologous, Pediatrics, Hematopoietic cell transplantation, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

More than 20% of allogeneic hematopoietic cell transplantations (HCTs) are performed in children and adolescents at a large number of relatively small centers. Unlike adults, at least one-third of HCTs in children are performed for rare, nonmalignant indications. Clinical trials to improve HCT outcomes in children have been limited by small numbers and these pediatric-specific features. The need for a larger number of pediatric HCT centers to participate in trials has led to the involvement of international collaborative groups. Representatives of the Pediatric Blood and Marrow Transplant Consortium, European Group for Blood and Marrow Transplantation's Pediatric Working Group, International Berlin-Frankfurt-Munster (iBFm) Stem Cell Transplantation Committee, and Children's Oncology Group's Hematopoietic Stem Cell Transplantation Discipline Committee met on October 3, 2012, in Frankfurt, Germany to develop a consensus on the highest priorities in pediatric HCT. In addition, it explored the creation of an international consortium to develop studies focused on HCT in children and adolescents. This meeting led to the creation of an international HCT network, dubbed the Westhafen Intercontinental Group, to develop worldwide priorities and strategies to address pediatric HCT issues. This review outlines the priorities of need as identified by this consensus group.

Published
2013

6. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

Author

Abinun, Mario, Aggarwal, Amita, Akikusa, Jonathan, Al-Mayouf, Sulaiman, Alessio, Maria, Anton, Jordi, Apaz, Maria Teresa, Astigarraga, Itziar, Avcin, Tadej, Ayaz, Nuray Aktay, Barone, Patrizia, Bica, Bianca, Bolt, Isabel, Bovis, Francesca, Breda, Luciana, Chasnyk, Vyacheslav, Cimaz, Rolando, Corona, Fabrizia, Cron, Randy Q., Cuttica, Ruben, Davì, Sergio, Davidsone, Zane, De Cunto, Carmen, De Inocencio, Jaime, Demirkaya, Erkan, Eisenstein, Eli M., Enciso, Sandra, Espada, Graciela, Fischbach, Michel, Frosch, Michael, Gallizzi, Romina, Gamir, Maria Luz, Gao, Yi-Jin, Griffin, Thomas, Grom, Alexei, Hashad, Soad, Hennon, Teresa, Henter, Jan-Inge, Horne, AnnaCarin, Horneff, Gerd, Huasong, Zeng, Huber, Adam, Ilowite, Norman, Insalaco, Antonella, Ioseliani, Maka, Jeng, Michael, Kapović, Agneza Marija, Kasapcopur, Ozgur, Khubchandani, Raju, Kitoh, Toshiyuki, Koné-Paut, Isabelle, de Oliveira, Sheila Knupp Feitosa, Lattanzi, Bianca, Lehmberg, Kai, Lepore, Loredana, Li, Caifeng, Lipton, Jeffrey M., Magni-Manzoni, Silvia, Maritsi, Despoina, Martini, Alberto, McCurdy, Deborah, Merino, Rosa, Micalizzi, Concetta, Miettunen, Paivi, Minoia, Francesca, Mulaosmanovic, Velma, Nichols, Kim E., Nielsen, Susan, Ozen, Seza, Pal, Priyankar, Prahalad, Sampath, Ravelli, Angelo, Rigante, Donato, Rumba-Rozenfelde, Ingrida, Ruperto, Nicolino, Russo, Ricardo, Magalhães, Claudia Saad, Sanner, Helga, Sewairi, Wafaa Mohamed Saad, Shenoi, Susan, Artur Silva, Clovis, Stanevicha, Valda, Sterba, Gary, Stine, Kimo C., Susic, Gordana, Sztajnbok, Flavio, Takei, Syuji, Trauzeddel, Ralf, Tsitsami, Elena, Unsal, Erbil, Uziel, Yosef, Vougiouka, Olga, Wallace, Carol A., Weaver, Lehn, E. Weiss, Jennifer, Weitzman, Sheila, Wouters, Carine, Wulffraat, Nico, Zletni, Mabruka, Arico, Maurizio, Egeler, R. Maarten, Filipovich, Alexandra H., Gadner, Helmut, Imashuku, Shinsaku, Janka, Gritta, Ladisch, Stephan, McClain, Ken L., and Webb, David

Published
2017
Full Text
View/download PDF

7. Clinicogenomic associations in childhood Langerhans cell histiocytosis:an international cohort study

Author

Kemps, Paul G., Zondag, Timo C.E., Arnardóttir, Helga B., Solleveld-Westerink, Nienke, Borst, Jelske, Steenwijk, Eline C., van Egmond, Demi, Swennenhuis, Joost F., Stelloo, Ellen, Trambusti, Irene, Verdijk, Robert M., van Noesel, Carel J.M., Cleven, Arjen H.G., Scheijde-Vermeulen, Marijn A., Koudijs, Marco J., Krsková, Lenka, Hawkins, Cynthia, Egeler, R. Maarten, Brok, Jesper, von Bahr Greenwood, Tatiana, Svojgr, Karel, Beishuizen, Auke, van Laar, Jan A.M., Pötschger, Ulrike, Hutter, Caroline, Sieni, Elena, Minkov, Milen, Abla, Oussama, van Wezel, Tom, van den Bos, Cor, van Halteren, Astrid G.S., Kemps, Paul G., Zondag, Timo C.E., Arnardóttir, Helga B., Solleveld-Westerink, Nienke, Borst, Jelske, Steenwijk, Eline C., van Egmond, Demi, Swennenhuis, Joost F., Stelloo, Ellen, Trambusti, Irene, Verdijk, Robert M., van Noesel, Carel J.M., Cleven, Arjen H.G., Scheijde-Vermeulen, Marijn A., Koudijs, Marco J., Krsková, Lenka, Hawkins, Cynthia, Egeler, R. Maarten, Brok, Jesper, von Bahr Greenwood, Tatiana, Svojgr, Karel, Beishuizen, Auke, van Laar, Jan A.M., Pötschger, Ulrike, Hutter, Caroline, Sieni, Elena, Minkov, Milen, Abla, Oussama, van Wezel, Tom, van den Bos, Cor, and van Halteren, Astrid G.S.

Abstract

Langerhans cell histiocytosis (LCH) is a rare neoplastic disorder caused by somatic genetic alterations in hematopoietic precursor cells differentiating into CD1a+/CD207+ histiocytes. LCH clinical manifestation is highly heterogeneous. BRAF and MAP2K1 mutations account for ~80% of genetic driver alterations in neoplastic LCH cells. However, their clinical associations remain incompletely understood. Here, we present an international clinicogenomic study of childhood LCH, investigating 377 patients genotyped for at least BRAFV600E. MAPK pathway gene alterations were detected in 300 (79.6%) patients, including 191 (50.7%) with BRAFV600E, 54 with MAP2K1 mutations, 39 with BRAF exon 12 mutations, 13 with rare BRAF alterations, and 3 with ARAF or KRAS mutations. Our results confirm that BRAFV600E associates with lower age at diagnosis and higher prevalence of multisystem LCH, high-risk disease, and skin involvement. Furthermore, BRAFV600E appeared to correlate with a higher prevalence of central nervous system (CNS)–risk bone lesions. In contrast, MAP2K1 mutations associated with a higher prevalence of single-system (SS)-bone LCH, and BRAF exon 12 deletions seemed to correlate with more lung involvement. Although BRAFV600E correlated with reduced event-free survival in the overall cohort, neither BRAF nor MAP2K1 mutations associated with event-free survival when patients were stratified by disease extent. Thus, the correlation of BRAFV600E with inferior clinical outcome is (primarily) driven by its association with disease extents known for high rates of progression or relapse, including multisystem LCH. These findings advance our understanding of factors underlying the remarkable clinical heterogeneity of LCH but also question the independent prognostic value of lesional BRAFV600E status.

Published
2023

8. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

Author

Burke, Michael J., Verneris, Michael R., Le Rademacher, Jennifer, He, Wensheng, Abdel-Azim, Hisham, Abraham, Allistair A., Auletta, Jeffery J., Ayas, Mouhab, Brown, Valerie I., Cairo, Mitchell S., Chan, Ka Wah, Diaz Perez, Miguel A., Dvorak, Christopher C., Egeler, R. Maarten, Eldjerou, Lamis, Frangoul, Haydar, Guilcher, Gregory M.T., Hayashi, Robert J., Ibrahim, Ahmed, Kasow, Kimberly A., Leung, Wing H., Olsson, Richard F., Pulsipher, Michael A., Shah, Niketa, Shah, Nirali N., Thiel, Elizabeth, Talano, Julie-An, and Kitko, Carrie L.

Published
2015
Full Text
View/download PDF

15. Challenges and Opportunities for International Cooperative Studies in Pediatric Hematopoeitic Cell Transplantation: Priorities of the Westhafen Intercontinental Group

Author

Schultz, Rudolph Kirk R., Baker, Kevin Scott, Boelens, Jaap J., Bollard, Catherine M., Egeler, R. Maarten, Cowan, Mort, Ladenstein, Ruth, Lankester, Arjan, Locatelli, Franco, Lawitschka, Anita, Levine, John E., Loh, Mignon, Nemecek, Eneida, Niemeyer, Charlotte, Prasad, Vinod K., Rocha, Vanderson, Shenoy, Shalini, Strahm, Brigitte, Veys, Paul, Wall, Donna, Bader, Peter, Grupp, Stephan A., Pulsipher, Michael A., and Peters, Christina

Published
2013
Full Text
View/download PDF

27. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion

Author

Coury, Fabienne, Annels, Nicola, Rivollier, Aymeric, Olsson, Selma, Santoro, Alessandra, Speziani, Carole, Azocar, Olga, Flacher, Monique, Djebali, Sophia, Tebib, Jacques, Brytting, Maria, Egeler, R Maarten, Rabourdin-Combe, Chantal, Henter, Jan-Inge, Arico, Maurizio, and Delprat, Christine

Subjects
Langerhans-cell histiocytosis -- Research, Dendritic cells -- Research, Flow cytometry -- Usage, Gene expression -- Research, Lymphadenopathy -- Research, Interleukins -- Research
Abstract

IL-17A is a T cell-specific cytokine that is involved in chronic inflammations, such as Mycobacterium infection, Crohn's disease, rheumatoid arthritis and multiple sclerosis. Mouse models have explained the molecular basis of IL-17A production and have shown that IL-17A has a positive effect not only on granuloma formation and neurodegeneration through unknown mechanisms, but also on bone resorption through Receptor activator of NF-[kappa]B ligand (RANKL) induction in osteoblasts. Langerhans cell histiocytosis (LCH) is a rare disease of unknown etiology, lacking an animal model, that cumulates symptoms that are found separately in various IL-17A-related diseases, such as aggressive chronic granuloma formation, bone resorption and soft tissue lesions with occasional neurodegeneration. We examined IL-17A in the context of LCH and found that there were high serum levels of IL-17A during active LCH and unexpected IL-17A synthesis by dendritic cells (DCs), the major cell type in LCH lesions. We also found an IL-17A-dependent pathway for DC fusion, which was highly potentiated by IFN-[gamma] and led to giant cells expressing three major tissue-destructive enzymes: tartrate resistant acidic phosphatase and matrix metalloproteinases 9 and 12. IFN-[gamma] expression has been previously documented in LCH and observed in IL-17A-related diseases. Notably, serum IL-17A-dependent fusion activity correlates with LCH activity. Thus, IL-17A and IL-17A-stimulated DCs represent targets that may have clinical value in the treatment of LCH and other IL-17A-related inflammatory disorders., Author(s): Fabienne Coury [1, 2, 3, 4, 5]; Nicola Annels [6]; Aymeric Rivollier [1, 2, 3, 4]; Selma Olsson [7]; Alessandra Santoro [8, 9]; Carole Speziani [1, 2, 3, 4]; [...]

Published
2008
Full Text
View/download PDF

28. Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis

Author

Kemps, Paul G., Zondag, Timo C., Steenwijk, Eline C., Andriessen, Quirine, Borst, Jelske, Vloemans, Sandra, Roelen, Dave L., Voortman, Lenard M., Verdijk, Robert M., van Noesel, Carel J.M., Cleven, Arjen H.G., Hawkins, Cynthia, Lang, Veronica, de Ru, Arnoud H., Janssen, George M.C., Haasnoot, Geert W., Franken, Kees L.M.C., van Eijk, Ronald, Solleveld-Westerink, Nienke, van Wezel, Tom, Egeler, R. Maarten, Beishuizen, Auke, van Laar, Jan A.M., Abla, Oussama, van den Bos, Cor, van Veelen, Peter A., van Halteren, Astrid G.S., Kemps, Paul G., Zondag, Timo C., Steenwijk, Eline C., Andriessen, Quirine, Borst, Jelske, Vloemans, Sandra, Roelen, Dave L., Voortman, Lenard M., Verdijk, Robert M., van Noesel, Carel J.M., Cleven, Arjen H.G., Hawkins, Cynthia, Lang, Veronica, de Ru, Arnoud H., Janssen, George M.C., Haasnoot, Geert W., Franken, Kees L.M.C., van Eijk, Ronald, Solleveld-Westerink, Nienke, van Wezel, Tom, Egeler, R. Maarten, Beishuizen, Auke, van Laar, Jan A.M., Abla, Oussama, van den Bos, Cor, van Veelen, Peter A., and van Halteren, Astrid G.S.

Abstract

Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder of hematopoietic origin characterized by inflammatory lesions containing clonal histiocytes (LCH-cells) intermixed with various immune cells, including T cells. In 50–60% of LCH-patients, the somatic BRAFV600E driver mutation, which is common in many cancers, is detected in these LCH-cells in an otherwise quiet genomic landscape. Non-synonymous mutations like BRAFV600E can be a source of neoantigens capable of eliciting effective antitumor CD8+ T cell responses. This requires neopeptides to be stably presented by Human Leukocyte Antigen (HLA) class I molecules and sufficient numbers of CD8+ T cells at tumor sites. Here, we demonstrate substantial heterogeneity in CD8+ T cell density in n = 101 LCH-lesions, with BRAFV600E mutated lesions displaying significantly lower CD8+ T cell:CD1a+ LCH-cell ratios (p = 0.01) than BRAF wildtype lesions. Because LCH-lesional CD8+ T cell density had no significant impact on event-free survival, we investigated whether the intracellularly expressed BRAFV600E protein is degraded into neopeptides that are naturally processed and presented by cell surface HLA class I molecules. Epitope prediction tools revealed a single HLA class I binding BRAFV600E derived neopeptide (KIGDFGLATEK), which indeed displayed strong to intermediate binding capacity to HLA-A*03:01 and HLA-A*11:01 in an in vitro peptide-HLA binding assay. Mass spectrometry-based targeted peptidomics was used to investigate the presence of this neopeptide in HLA class I presented peptides isolated from several BRAFV600E expressing cell lines with various HLA genotypes. While the HLA-A*02:01 binding BRAF wildtype peptide KIGDFGLATV was traced in peptides isolated from all five cell lines expressing this HLA subtype, KIGDFGLATEK was not detected in the H

Published
2020

31. Management of epstein-barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution

Author

Annels, Nicola E., Kalpoe, Jayant S., Bredius, Robbert G.M., Claas, Eric C., Kroes, Aloys C.M., Hislop, Andrew D., van Baarle, Debbie, Egeler, R. Maarten, van Tol, Maarten J.D., and Lankester, Arjan C.

Subjects
Epstein-Barr virus -- Physiological aspects, Epstein-Barr virus -- Research, Lymphoproliferative disorders -- Development and progression, Viremia -- Measurement, Viremia -- Research, Stem cells -- Transplantation, Stem cells -- Complications and side effects, Health, Health care industry
Published
2006

32. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation

Author

Marshall, G M, Dalla Pozza, L, Sutton, R, Ng, A, de Groot-Kruseman, H A, van der Velden, V H, Venn, N C, van den Berg, H, de Bont, E SJM, Egeler, R Maarten, Hoogerbrugge, P M, Kaspers, G JL, Bierings, M B, van der Schoot, E, van Dongen, J, Law, T, Cross, S, Mueller, H, de Haas, V, Haber, M, Révész, T, Alvaro, F, Suppiah, R, Norris, M D, and Pieters, R

Published
2013
Full Text
View/download PDF

36. Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis

Author

Kemps, Paul G., primary, Zondag, Timo C., additional, Steenwijk, Eline C., additional, Andriessen, Quirine, additional, Borst, Jelske, additional, Vloemans, Sandra, additional, Roelen, Dave L., additional, Voortman, Lenard M., additional, Verdijk, Robert M., additional, van Noesel, Carel J. M., additional, Cleven, Arjen H. G., additional, Hawkins, Cynthia, additional, Lang, Veronica, additional, de Ru, Arnoud H., additional, Janssen, George M. C., additional, Haasnoot, Geert W., additional, Franken, Kees L. M. C., additional, van Eijk, Ronald, additional, Solleveld-Westerink, Nienke, additional, van Wezel, Tom, additional, Egeler, R. Maarten, additional, Beishuizen, Auke, additional, van Laar, Jan A. M., additional, Abla, Oussama, additional, van den Bos, Cor, additional, van Veelen, Peter A., additional, and van Halteren, Astrid G. S., additional

Published
2020
Full Text
View/download PDF

37. The coming of age of Langerhans cell histiocytosis

Author

Allen, Carl E., primary, Beverley, Peter C. L., additional, Collin, Matthew, additional, Diamond, Eli L., additional, Egeler, R. Maarten, additional, Ginhoux, Florent, additional, Glass, Christopher, additional, Minkov, Milen, additional, Rollins, Barrett J., additional, and van Halteren, Astrid, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results